En‐Tzu Tang

521 total citations
17 papers, 391 citations indexed

About

En‐Tzu Tang is a scholar working on Oncology, Molecular Biology and Hepatology. According to data from OpenAlex, En‐Tzu Tang has authored 17 papers receiving a total of 391 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Hepatology. Recurrent topics in En‐Tzu Tang's work include Bone health and treatments (5 papers), Liver physiology and pathology (4 papers) and Cancer Mechanisms and Therapy (3 papers). En‐Tzu Tang is often cited by papers focused on Bone health and treatments (5 papers), Liver physiology and pathology (4 papers) and Cancer Mechanisms and Therapy (3 papers). En‐Tzu Tang collaborates with scholars based in United States, China and Canada. En‐Tzu Tang's co-authors include David Macarios, Sacha Satram‐Hoang, Primal Kaur, David L. Kendler, Suresh Siddhanti, Nick Freemantle, Jeff Borenstein, Yanni Zhang, Zhiqiang Du and Decker F. Walker and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

En‐Tzu Tang

14 papers receiving 380 citations

Peers

En‐Tzu Tang
Inmaculada Ros Spain
Melissa S. Dillmon United States
Vassiliki M. Cartsos United States
Elaine Wong Hong Kong
O. Filleul Belgium
Hesham Elghazaly Egypt
Gennaro De Rosa Italy
María Luisa Antelo Spain
Federico Discepola Canada
J. Mould United Kingdom
Inmaculada Ros Spain
En‐Tzu Tang
Citations per year, relative to En‐Tzu Tang En‐Tzu Tang (= 1×) peers Inmaculada Ros

Countries citing papers authored by En‐Tzu Tang

Since Specialization
Citations

This map shows the geographic impact of En‐Tzu Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by En‐Tzu Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites En‐Tzu Tang more than expected).

Fields of papers citing papers by En‐Tzu Tang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by En‐Tzu Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by En‐Tzu Tang. The network helps show where En‐Tzu Tang may publish in the future.

Co-authorship network of co-authors of En‐Tzu Tang

This figure shows the co-authorship network connecting the top 25 collaborators of En‐Tzu Tang. A scholar is included among the top collaborators of En‐Tzu Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with En‐Tzu Tang. En‐Tzu Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Wang, Sheng, Rong Su, Xufeng Li, et al.. (2024). BC3195, a novel ADC targeting CDH3: Preliminary results of a first-in-human phase I study in patients with advanced solid malignancies.. Journal of Clinical Oncology. 42(16_suppl). e15008–e15008.
2.
Du, Juan, Baijun Fang, Li J, et al.. (2021). A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China. International Journal of Hematology. 113(3). 422–429. 5 indexed citations
3.
4.
5.
Liede, Alexander, Rohini K. Hernandez, En‐Tzu Tang, et al.. (2018). Epidemiology of benign giant cell tumor of bone in the Chinese population. Journal of bone oncology. 12. 96–100. 22 indexed citations
6.
Yin, Hong, Xian Jia, Xiaojie Guo, et al.. (2018). Patient's T Cell Functionality Determines Blinatumomab-Mediated Killing of B-ALL Leukemia Cells. Blood. 132(Supplement 1). 4079–4079.
7.
Du, Zhiqiang, Sean Caenepeel, Yuqing Shen, et al.. (2016). Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma. Molecular Cancer Therapeutics. 15(6). 1227–1237. 18 indexed citations
8.
Zhang, Yanni, En‐Tzu Tang, & Zhiqiang Du. (2016). Detection of MET Gene Copy Number in Cancer Samples Using the Droplet Digital PCR Method. PLoS ONE. 11(1). e0146784–e0146784. 32 indexed citations
9.
Qiu, Miao‐Zhen, et al.. (2016). Evaluation of MET and HER2 expression in primary and metastatic tumor in Chinese advanced gastric cancer patients.. Journal of Clinical Oncology. 34(15_suppl). e15538–e15538.
10.
Peng, Zhi, Zhongwu Li, Jing Gao, et al.. (2015). Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics. 14(11). 2634–2641. 19 indexed citations
11.
Xu, Rui‐Hua, Miao‐Zhen Qiu, Yixin Zhou, et al.. (2015). Evaluation of tumor MET protein expression, MET gene amplification, and HER2 expression in Chinese patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer.. Journal of Clinical Oncology. 33(15_suppl). 4048–4048. 2 indexed citations
12.
Kendler, David L., David Macarios, Michael Lillestol, et al.. (2013). Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. Menopause The Journal of The North American Menopause Society. 21(1). 25–32. 25 indexed citations
13.
Freemantle, Nick, David L. Kendler, Primal Kaur, et al.. (2011). Open-label, Crossover Study Evaluating the Adherence, Preference, and Satisfaction of Denosumab and Alendronate Treatment in Postmenopausal Women: Results of the Second Year of the Study. Journal of Clinical Densitometry. 14(2). 158–159. 1 indexed citations
14.
Freemantle, Nick, Sacha Satram‐Hoang, En‐Tzu Tang, et al.. (2011). Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporosis International. 23(1). 317–326. 219 indexed citations
15.
McClung, Michael R., Nick Freemantle, Primal Kaur, et al.. (2011). The Denosumab Adherence, Preference, Satisfaction (DAPS) Study: Bone Mineral Density Results at 24 Months. Journal of Clinical Densitometry. 14(2). 159–159. 1 indexed citations
16.
Jiang, Jiming & En‐Tzu Tang. (2010). The best EBLUP in the Fay–Herriot model. Annals of the Institute of Statistical Mathematics. 63(6). 1123–1140. 4 indexed citations
17.
Wadey, Veronica, et al.. (2007). Canadian multidisciplinary core curriculum for musculoskeletal health.. PubMed. 34(3). 567–80. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Inmaculada Ros Breakdown of academic impact, for papers by Melissa S. Dillmon Breakdown of academic impact, for papers by Vassiliki M. Cartsos Breakdown of academic impact, for papers by Elaine Wong Breakdown of academic impact, for papers by O. Filleul Breakdown of academic impact, for papers by Hesham Elghazaly Breakdown of academic impact, for papers by Gennaro De Rosa Breakdown of academic impact, for papers by María Luisa Antelo Breakdown of academic impact, for papers by Federico Discepola Breakdown of academic impact, for papers by J. Mould
Rankless by CCL
2026